Silodosin is a selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia by relaxing smooth muscle in the bladder neck and prostate to… Read more













![Chemical structure of 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F885340-11-4-1-3-Benzoyloxypropyl-23-dihydro-5-2R-2-2-2-222-trifluoroethoxyphenoxyethylaminopropyl-1H-indole-7-carbonitrile.png&w=3840&q=75)
![Chemical structure of 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile acetyl-L-glutamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1771736-90-3-1-3-Benzoyloxypropyl-23-dihydro-5-2R-2-2-2-222-trifluoroethoxyphenoxyethylaminopropyl-1H-indole-7-carbonitrile-acetyl-L-glutamate.png&w=3840&q=75)
![Chemical structure of 1-[3-(Benzyloxy)propyl]-5-formylindoline-7-carbonitrile](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1375180-30-5-1-3-Benzyloxypropyl-5-formylindoline-7-carbonitrile.png&w=3840&q=75)


![Chemical structure of 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl Methanesulfonate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F160969-03-9-2-2-222-Trifluoroethoxyphenoxyethyl-Methanesulfonate.png&w=3840&q=75)
![Chemical structure of 2-[[2-(2,2,2-Trifluoroethoxy)phenoxy]methyl]-1,3-dioxolane](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1269801-74-2-2-2-222-Trifluoroethoxyphenoxymethyl-13-dioxolane.png&w=3840&q=75)





![Chemical structure of 5-(2-Aminopropyl)-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1338365-54-0-5-2-Aminopropyl-1-3-benzoyloxypropyl-23-dihydro-1H-indole-7-carbonitrile.png&w=3840&q=75)
![Chemical structure of 5-[(2R)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2R,3R)-2,3-Dihydroxybutanedioate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F239463-85-5-5-2R-2-Aminopropyl-1-3-benzoyloxypropyl-23-dihydro-1H-indole-7-carbonitrile-2R3R-23-Dihydroxybutanedioate.png&w=3840&q=75)
![Chemical structure of 5-[(2S)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1201180-97-3-5-2S-2-Aminopropyl-1-3-benzoyloxypropyl-23-dihydro-1H-indole-7-carbonitrile.png&w=3840&q=75)
![Chemical structure of 5-[(2S)-2-Aminopropyl]-1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-indole-7-carbonitrile (2S,3S)-2,3-dihydroxysuccinate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1646626-51-8-5-2S-2-Aminopropyl-1-3-benzoyloxypropyl-23-dihydro-1H-indole-7-carbonitrile-2S3S-23-dihydroxysuccinate.png&w=3840&q=75)



![Chemical structure of N-Des[2-(1-methyl-2-pyrrolidinyl)ethyl] Udenafil](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F319491-68-4-N-Des2-1-methyl-2-pyrrolidinylethyl-Udenafil.png&w=3840&q=75)

















Silodosin is a selective α1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia by relaxing smooth muscle in the bladder neck and prostate to improve urinary flow. To support the rigorous analytical testing and quality control of this therapeutic agent, this category offers a comprehensive range of reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. These materials are essential for accurate impurity profiling and the validation of stability-indicating analytical methods, such as HPLC or LC-MS/MS, ensuring compliance with international regulatory standards. By providing characterized reference materials, these compounds facilitate the precise identification and quantification of process-related and degradation impurities, as well as enabling robust pharmacokinetic investigations. Such analytical resources are vital for maintaining the safety, efficacy, and consistent quality of Silodosin formulations throughout the drug development lifecycle.